At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 35 enrolled
Drug / intervention
teriparatidedrug
Likely dose
teriparatide 20 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effects of Teriparatide on Bone Microarchitecture as Determined by High Resolution Magnetic Resonance Imaging and Digital Topological Analysis
In Brief
A Phase 4 clinical trial evaluating teriparatide for Osteoporosis, Postmenopausal. Completed, enrolled 35 participants across 6 sites in 2 countries.
Detailed Summary
The purpose of this study is to use imaging technologies to demonstrate the effects of teriparatide on bone structure following 18 to 24 months of therapy in postmenopausal women with osteoporosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis, Postmenopausal
CountriesCanada, United States
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2007
First PostedNov 2007
Primary CompletionOct 2010
Study CompletionMay 2011
TodayJul 2026
First PostedNov 14, 2007
Enrollment StartNov 1, 2007
Primary CompletionOct 1, 2010
Study CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 18.6 years ago
Interventions
teriparatidedrug
20 mcg teriparatide subcutaneous injection per day for 18 months, with possibility to continue for 24 months